Chemotherapeutic strategies for treatment of colorectal cancer: Present and future developments

Clinical colorectal cancer

Volumn 1, Issue 2, 2001, Pages 121-127

  Backus, Harold H J ^a   Rustum, Youcef M ^b   Van Groeningen, Cornelius J ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; HUMAN; METABOLISM; PROGNOSIS; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035427964     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2001.n.013     Document Type: Note

References (45)

1. JA Wils Adjuvant treatment in Dukes' B and C disease Ann Oncol 11 suppl 3 2000 37 43
2. J Wils P O'Dwyer R Labianca Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives Ann Oncol 12 2001 13 22
3. G Riethmuller E Holz G Schlimok Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial J Clin Oncol 16 1998 1788 1794
4. JB Vermorken AM Claessen H van Tinteren Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial Lancet 353 1999 345 350
5. YM Rustum S Cao New drugs in therapy of colorectal cancer: preclinical studies Semin Oncol 26 1999 612 620
6. H Calvert An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents Semin Oncol 26 1999 3 10
7. AL Jackman R Kimbell HE Ford Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations Eur J Cancer 35 suppl 1 1999 S3 S8
8. GJ Peters CL van der Wilt CJ van Moorsel Basis for effective combination cancer chemotherapy with antimetabolites Pharmacol Ther 87 2000 227 253
9. C Aschele C Baldo AF Sobrero Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro Clin Cancer Res 4 1998 1323 1330
10. U Vanhoefer A Harstrick W Achterrath Irinotecan in the treatment of colorectal cancer: clinical overview J Clin Oncol 19 2001 1501 1518
11. JI Grove PF Searle SJ Weedon Virus-directed enzyme prodrug therapy using CB1954 Anticancer Drug Des 14 1999 461 472
12. TA Drixler IH Rinkes ED Ritchie Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy Cancer Res 60 2000 1761 1765
13. RB Diasio Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines Drugs 58 1999 119 126
14. S Mani H Hochster T Beck Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer J Clin Oncol 18 2000 2894 2901
15. J Marsh P Catalano J Huang Phase II trial of oral fluorouracil (5-FU) + oral eniluracil (GW776C85) administered over 28 days for patients with advanced colorectal cancer (E4296): a trial of the Eastern Cooperative Oncology Group (ECOG) Proc Am Soc Clin Oncol 20 2001 138a (Abstract #547).
16. R Diasio Orzel/UFT investigators meeting Oncology 14 suppl 9 2000 13 95
17. A Sulkes SE Benner RM Canetta Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer J Clin Oncol 16 1998 3461 3475
18. R Pazdur JY Douillard JR Skillings Multicenter phase III study of 5-fluorouracil (5-FU) or UFTTM in combination with leucovorin (LV) in patients with metastatic colorectal cancer Proc Am Soc Clin Oncol 18 1999 263a (Abstract #1009).
19. J Carmichael T Popiela D Radstone Randomized comparative study of ORZEL® (oral uracil/tegafur (UFTTM) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer Proc Am Soc Clin Oncol 18 1999 264a (Abstract #1015).
20. CJ van Groeningen GJ Peters JH Schornagel Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors J Clin Oncol 18 2000 2772 2779
21. A Ohtsu H Baba Y Sakata Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group Br J Cancer 83 2000 141 145
22. J Verweij Rational design of new tumoractivated cytotoxic agents Oncology 57 suppl 1 1999 9 15
23. JV Cox R Pazdur A Thibault A phase III trial of XELODATM (capecitabine) in previously untreated advanced/metastatic colorectal cancer Proc Am Soc Clin Oncol 18 1999 265a (Abstract #1016).
24. C Twelves P Harper E Van Cutsem A phase III trial (S014796) of Xeloda™ (capecitabine) in previously untreated advanced/metastatic colorectal cancer Proc Am Soc Clin Oncol 18 1999 263a (Abstract #1010).
25. GK Schwartz A Harstrick M Gonzalez Baron Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials Eur J Cancer 35 suppl 1 1999 S9 S13
26. CJ Punt Trimetrexate as a biochemical modulator of 5-fluorouracil and leucovorin in colorectal cancer Semin Oncol 27 suppl 10 2000 88 90
27. E Van Cutsem Raltitrexed (Tomudex) in combination treatment for colorectal cancer: new perspectives Eur J Cancer 35 suppl 1 1999 S1 S2
28. K Fizazi M Ducreux P Ruffie Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer J Clin Oncol 18 2000 2293 2300
29. F Levi R Zidani JL Misset Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy Lancet 350 1997 681 686
30. F Maindrault-Goebel A de Gramont C Louvet Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer Ann Oncol 11 2000 1477 1483
31. U Vanhoefer A Harstrick CH Kohne Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer J Clin Oncol 17 1999 907 913
32. JY Douillard D Cunningham AD Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047
33. LB Saltz JV Cox C Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 2000 905 914
34. N Kemeny J Daly B Reichman Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial Ann Intern Med 107 1987 459 465
35. T Nakamoto H Inagawa K Takagi A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors Anticancer Res 20 2000 4087 4096
36. DM Pritchard AJ Watson CS Potten Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5- fluorouracil: evidence for the involvement of RNA perturbation Proc Natl Acad Sci U S A 94 1997 1795 1799
37. D Farrugia P Johnston Pharmacodynamic measurements and predictors of response to thymidylate synthase inhibitors A Jackman Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy 1999 Humana Press Totowa 383 396
38. B Dolnick K Lu M Yin Recent advances in the study of rTS proteins. rTS expression during growth and in response to thymidylate synthase inhibitors in human tumor cells Adv Enzyme Regul 37 1997 95 109
39. D Salonga KD Danenberg M Johnson Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase Clin Cancer Res 6 2000 1322 1327
40. P Rougier E Mitry Colorectal cancer chemotherapy: irinotecan Semin Oncol 27 suppl 10 2000 138 143
41. E Chu DM Koeller JL Casey Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase Proc Natl Acad Sci U S A 88 1991 8977 8981
42. E Chu T Takechi KL Jones Thymidylate synthase binds to cmyc RNA in human colon cancer cells and in vitro Mol Cell Biol 15 1995 179 185
43. J Ju J Pedersen-Lane F Maley Regulation of p53 expression by thymidylate synthase Proc Natl Acad Sci U S A 96 1999 3769 3774
44. SI Lee MK Brown A Eastman Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines Biochem Pharmacol 58 1999 1713 1721
45. PP Claudio M Caputi A Giordano The RB2/p130 gene: the latest weapon in the war against lung cancer? Clin Cancer Res 6 2000 754 764